Print this page
-
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII.
Protocol: 142602Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients with Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma.
Protocol: 142502Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII.
Protocol: 142602Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System
- 1
- 2